Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

[Not Available].

Norian LA, Kucaba TA, Earel JK, Knutson T, Vanoosten RL, Griffith TS.

J Oncol. 2009;2009:408038. Epub 2009 Jun 14.

2.

TRAIL gene therapy: from preclinical development to clinical application.

Griffith TS, Stokes B, Kucaba TA, Earel JK Jr, VanOosten RL, Brincks EL, Norian LA.

Curr Gene Ther. 2009 Feb;9(1):9-19. Review.

3.

Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity.

VanOosten RL, Earel JK Jr, Griffith TS.

Apoptosis. 2007 Mar;12(3):561-71. Epub 2006 Dec 30.

PMID:
17195089
4.

Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.

VanOosten RL, Earel JK Jr, Griffith TS.

Cancer Gene Ther. 2006 Jun;13(6):628-32.

PMID:
16456549
6.

Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.

Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, Leidal K, Nauseef WM, Griffith TS.

Blood. 2005 Nov 15;106(10):3474-82. Epub 2005 Jul 21.

Supplemental Content

Loading ...
Support Center